These subgroup findings suggest that IMD may be more likely among patients with advanced-stage HER2+ breast cancer who receive trastuzumab monotherapy as compared to chemotherapy or another HER2-targeted agent. This evidence concerns the gene ERBB2 and breast carcinoma.